Albireo to Report Second Quarter 2021 Financial Results on August 5
29 Juli 2021 - 02:30PM
Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company
developing novel bile acid modulators, today announced that
management will host a conference call and live audio webcast
at 10:00 a.m. ET on August 5, 2021, to provide a business
update and review the company’s financial results for the second
quarter ended June 30, 2021.
To access the live conference call by phone, please dial
877-407-0792 (domestic) or 201-689-8263 (international), and
provide the access code 13720893. A live audio webcast will be
accessible from the Media & Investors page of Albireo’s
website, https://ir.albireopharma.com/. To ensure a timely
connection to the webcast, it is recommended that users register at
least 15 minutes prior to the start time. An archived version of
the webcast will be available for replay in the Events &
Presentations section of the Media & Investors page of
Albireo’s website for 3 months following the event.
About Albireo
Albireo Pharma is a rare liver disease company focused on the
development of novel bile acid modulators to treat rare pediatric
and adult liver diseases. Albireo’s product, Bylvay, was approved
by the U.S. FDA as the first for the treatment of pruritus in
patients with all sub-types of progressive familial intrahepatic
cholestasis (PFIC), and is also being developed to treat other rare
pediatric cholestatic liver diseases with Phase 3 trials in
Alagille syndrome and biliary atresia, as well as an Open-label
Extension (OLE) study for PFIC. In Europe, Bylvay has been approved
for the treatment of PFIC and has been submitted for pricing and
reimbursement approval. The Company has also initiated a Phase 1
clinical trial for A3907 to advance development in adult
cholestatic liver disease, with IND-enabling studies moving ahead
with A2342 for viral and cholestatic liver disease. Albireo was
spun out from AstraZeneca in 2008 and is headquartered in Boston,
Massachusetts, with its key operating subsidiary in Gothenburg,
Sweden. The Boston Business Journal named Albireo one of the 2020
Best Places to Work in Massachusetts for the second consecutive
year. For more information on Albireo, please visit
www.albireopharma.com.
Media Contact: Colleen Alabiso,
857-356-3905, colleen.alabiso@albireopharma.comLisa Rivero,
617-947-0899, lisa.rivero@syneoshealth.com
Investor Contact: Hans Vitzthum, LifeSci Advisors,
LLC., 617-430-7578
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
Von Feb 2024 bis Mär 2024
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
Von Mär 2023 bis Mär 2024